#United States #New York #Class Action #ARD-101 #Aardvark

Overview of the Aardvark Therapeutics Class Action

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is currently facing a securities class action that raises significant concerns regarding the transparency and accuracy of information provided to investors. The allegations center on the company’s representation of its leading candidate drug, ARD-101, during its clinical trials. Investors are concerned that the claims made by Aardvark may have led them to make investment decisions based on an incomplete understanding of the risks involved.

Allegations and Stock Performance

According to the lawsuit, Aardvark overstated the clinical, regulatory, and commercial prospects of ARD-101, portraying it as a drug with minimal systemic exposure and no serious adverse events. The lawsuit alleges that these claims were misleading, particularly as new findings regarding the drug's safety began to emerge. As a result of the alleged misrepresentation, the market reacted unfavorably when the company announced a voluntary pause in its Phase 3 HERO trial, significant drops in stock price followed, wiping out substantial investor value.

Notably, shares that were initially priced at $16.00 during the offering in February 2025 plummeted to $4.57 by May 15, 2026—a staggering 71.4% decline within a matter of months. This drastic fall included a $7.02 per-share drop (56.2%) upon the announcement of the trial pause, followed by a further $2.16 reduction (32.1%) after the FDA's announcement of a full clinical hold on the drug's investigational new drug application.

Details Behind the Allegations

The crux of the lawsuit lies in the assertions made by Aardvark’s management regarding the safety profile of ARD-101. The company had indicated that the drug was gut-restricted with nearly 99% limited systemic absorption, despite ongoing safety evaluations. However, when reversible cardiac observations were reported during regular safety monitoring in a volunteer study, Aardvark’s claims were called into question. This led to the suspension of the HERO trial and a subsequent full clinical hold by the FDA, prompting investors to reevaluate the projected timeline for crucial trial data.

Further compounding the complications, analysts had sharply reduced their price targets for Aardvark shares in light of these developments—forecasts plummeting from as high as $29 to $7.

Importance of Safety Disclosures

The implications for investors are significant, especially considering that many purchased AARD securities based on the perceived viability of ARD-101 and the expected regulatory path detailed by the company. With new disclosures challenging prior assurances, many investors are left questioning their financial decisions and whether they can pursue recovery for their losses.

Frequently Asked Questions

1. Who is Eligible for the Class Action?
Investors who bought AARD stock between February 13, 2025, and May 14, 2026, and suffered financial losses may find eligibility in this class action.

2. What Misstatements are Alleged?
Key false claims revolve around the safety profile of ARD-101 and its market prospects, particularly in light of the trial delays and regulatory holds.

3. Where was the Class Action Filed?
The lawsuit is filed in the United States District Court for the Southern District of California.

4. What Should Investors Do Now?
Investors are advised to collect brokerage records to document their transactions and losses for potential inclusion in the class action.

5. Can I Recover Losses if I Sold My Shares?
Yes, eligibility is based on purchase dates, not current holdings, allowing previous shareholders who sold at a loss a chance to participate in the lawsuit.

Conclusion

The ongoing developments surrounding Aardvark Therapeutics and its lead drug ARD-101 illustrate the critical need for accurate safety disclosures in the biotech industry. As this class action unfolds, investors are called to stay informed about their rights and potential recovery opportunities. The deadline for appointment of lead plaintiffs is set for October 13, 2026, marking an important date for affected shareholders to prepare for action.

For more information about the class action and to find out if you are eligible to join, you can contact Joseph E. Levi, Esq., who is overseeing the case.